Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOZE5JN3ZWbHpwNHpwVV9TWmhYc0lLRi1FdUlHcFRXaVhUaUFKMl8wRmtsTlRpRVZ0X3lGTkxBN2NSWTJ2UzVXU2JSQlhNZFJGbVZHRWc2TlpXdldodzRoSGRiTkpmRGc1OFlCeFFDMG9NOTVraXNLdi1wekxBT1dscWkyQkZEUHVxWUZzZkFnT3gwTjBJS1hkeFFELXg3QXloM240eFRJbFlhbTBJLVJOam5LRkFuaXJQSzNNVWJnVkZkNlJCUEE?oc=5" target="_blank">Latest Advancements in Myelofibrosis Treatment: Key Updates from EHA and ASH 2025</a>&nbsp;&nbsp;<font color="#6f6f6f">EMJ</font>
October 11, 2026: Lilli Tagger vs Nikola Bartunkova: Set 1 Winner Prediction Market
Padres de Natanael Cano rompen el silencio tras retiro del cantante: "Es por el bien de nuestro hijo"
Vance says Microsoft replaced laid-off workers with foreign hires. Here’s what the visa data shows
LIVE | Atlanta weather: Power outages, tree damage remain as storm threat moves east
Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxObTlfc1UtSTRHMmlsVGhrbklKcXozMGJyYjV3Q1p4VGJESjRnWlNLSVlNTlJLel9nLUktaklCVzdZWE1ZX0tDeWJIM0VjdzhucWY2M0thckhJNDNMUWlhb1plamFYMlZUUzRYYS16U0RqalY5TXhrWkdCc2R0ZDFWXzMzdGF1Yl90ZWl2VVl1NUx6aEc4UXNVdDF3?oc=5" target="_blank">4 notable presentations from ASH 2025</a>&nbsp;&nbsp;<font color="#6f6f6f">UT MD Anderson</font>
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBtbnZQeGdHRk9RZ1FMY3N4UFplRndBMHozekhNX2lwSGJHMEktSEFyWVBhNWFDNlpPdWFIUjNaSkx3QjYwbUwzeU1oY09rak0wbjJmVVpjUkoxQ2Z2?oc=5" target="_blank">ASH 2025: New combination approach aims to make CAR T more durable in lymphoma</a>&nbsp;&nbsp;<font color="#6f6f6f">EurekAlert! Science News Releases</font>
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPdUQ5eTNLQ2NlcEVseWxEMGZ4Z29KRXlPNUZwZzlGcTd3Mzl4S0tCNjJ1ZjI5SnNvdktoS0NvY04xb0xoV0ZXOTltWm5aaTcxWjA1MUNwWDVETlBTeEE4c3dKWWpQb091NGtNaXBuWXhBR21wWWpWamZ4OTNpRHYyME9zTkliMHBGRF9JcGRfeVpPMWVRR1NPVmlFRGw5bVNRMl9IZEdtVVc1UGE3dGctbkNXUQ?oc=5" target="_blank">All Eyes Are on Novel Combination Therapies and Molecular Targets in MPN at ASH 2025</a>&nbsp;&nbsp;<font color="#6f6f6f">OncLive</font>
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNa1dwR0JGT3hXQUl1SXY4a2NYU28tc2xFbXdXM0RtcUxQa3NyWklTZzEwX1JEQndpMElZcmE3M2FicnFjV0hxR0ZsaHp3eEgxYmxZM1Jvckp0VnQtWkR2N28tU0VhOFhCenNSSUljeTRoSkY5aU5VNmRDal9GdldWOGpRLUY1azBuSVBCNHhNQ3pFS25aN2RCQ0c1N0pJdEFvVkdDcWp1Wkh5dGRSVXdHUV81a0d1MldieGRTa29vT3ZVVjhTV2ZPdlRn?oc=5" target="_blank">Sylvester Comprehensive Cancer Center at ASH 2025: Advancing Blood Cancer Science Through Collaboration</a>&nbsp;&nbsp;<font color="#6f6f6f">University of Miami</font>
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQcTE4X0FURktUVHkzZm53V182ODNyQWdFc2x4QktaZTkycWpOWk11LXN5S1YwZGxaUWNMYjBqTHk0eVNiY3k1MUxydHBEZmtoTlZBSUd6TkxBMEV1dVpuVG4xd1FEeTlRMjBjQ0luZlNHMW5XUDYwempiVEJXZDNULVFyZ0J0dUtOMmNUR2J5bURVaWJ6UnZPUi1zQ29BWWFMMWk0WFh5eG8wRElGdTJJOU8tVklDRC1KaXI0UFJwM2U?oc=5" target="_blank">New Research at ASH 2025 Points to More Targeted and Personalized Care for People with MPNs</a>&nbsp;&nbsp;<font color="#6f6f6f">news.cancerconnect.com</font>
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOQlBzLUJZWkhVWTRJaHFnc21fSnFNZ1IxVGhxMDhDT1BwVjByTVZKZjJPaTRfcG15OGJMeDQyQkVmd0xsN0dtOUdvdDZ2bV82THVvWDZ4cWZRNi1YUDZLQWFRczNoaUR5YWlyWmJFMDFlRlZpd0lRT25QVjNzT1doQml1djBHa2JnQnV0MWlNclE4bXVSejZvODV3NmF0Y2JSUFUwVw?oc=5" target="_blank">ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPV2xibUh2YjM1YkREcXM1S3BmWTE3dVZEdFZlUV9LU1lFbHdfVkNjeWwxVWRCVW5SNnJoS3Q0Qld0WDQ2VkhJWjRBUHo2VVJQZ3VNeUlYVkpXbzUxREJhSlVqREdiY1hOMkZvdk1vYm9OV1Q2UUQwemo1MWlrRWJwQnNXbEM2Smk4cV9fLV9PYXBuaGNNLW1SMk9n?oc=5" target="_blank">ASH 2025 Offers Data That Could Make Novel Therapies More Accessible</a>&nbsp;&nbsp;<font color="#6f6f6f">AJMC</font>
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxNcEFUQjd2THh3WnVDRDA1eE00UTB4OHBySkp6OTRUWFdfeFAtR2xHSUhvaHdZM3ZSaGtBd014Mk4tQXRHMTdEbGZTRl9UMG1FSkxtMUxzTDNpQ1RERG1XbTQteGJ0VUw2ZHdSSGtRWmdmaHM1Q3B6TC1CV1U2RGlOTWN2dUg?oc=5" target="_blank">ASH 2025: Previewing Novel BTK Strategies in CLL</a>&nbsp;&nbsp;<font color="#6f6f6f">Medscape</font>
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNeGg4dlJMaWo4elhTYThScGMwc1dOZlV4SHdkSkRhbHVOREdSd1NIZ0E3dGRsMGVsX293VXZia1BIR1ZMYUdiQWFzQzZiaVY0MlVNLWVrUThPTTY5cVhJWGdGU1puNFQ0b19GV1hGSm9SUENZWDVGSDN1WndtUU1vVkZoeUJpQ0s4VkZDY2FfUnhVTXNQMlRGcWhRbEwxM3ZleFdFdDVTYWtCNjdaSW9JdVVKeTExV0RWVTlN?oc=5" target="_blank">Roswell Park Leukemia Expert Led ASH 2025 Studies Assessing 2 New Treatment Strategies for Advanced AML</a>&nbsp;&nbsp;<font color="#6f6f6f">Roswell Park Comprehensive Cancer Center</font>
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQQ0F1WXNqMWF0RlRtanlFUjZfdy1qN1pMUENsbHBiUE5tejFYZ2RhaTZ3TnBMVzA0U09mbkh2cnZzOERCTEZ4MUxzV3lNbU1VR1N2SGVWOUZlbzlEek5TRXZqdmU0N0xua1oyRlRqVUpDN2hra0l0dXJDYW1RMlJpYjZZcGJUTmVKMXIwSTlBMHJNQTg0WnBzbldaNEFuaG1aYm5PUldkZk1wYjRLNG9ZZ2YxYkZIMTQ?oc=5" target="_blank">MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">The ASCO Post</font>
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOM2NDYkczaUdteFBoM1B5NkRtQ3NFXzlMVVpQU1ZPUjZyXzAzLU5CRW5fMktrTzRCYk1ha1ZZSHl6eWxydHBSdVVPOW5iemwtV3B1ZWljNlZDQUFSb0J4a2E0cXpTUzc5QUtaaDUwSEJZSVZWdzBKUWZveG9RWFF0c0ZPeWhicXZsOVQtWlQ0eldROWlHbG1IZ0cwWGhYTWM?oc=5" target="_blank">ASH 2025 | Top abstracts: What’s hot in acute myeloid leukemia?</a>&nbsp;&nbsp;<font color="#6f6f6f">aml-hub.com</font>
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPemdWbklXWkZmLThfZ2s4a0kzQnphYkpFUmhKYm9Dd3JMTU8yRVJIWDZPcXpEcDVaa211X09QQzhtUWtZNG4zYm9UbzNYU1RUVWtsako1UG9iU0FscTVaRHEwbkc2SDhqYUxIWTVmR1QtdXVZR3pVejVJT013NzJkN3UyQ3NJOWc5bEFLUHduM0NFdw?oc=5" target="_blank">J&J’s two-drug combo blocked tumors in advanced multiple myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">STAT</font>
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOWmRPbnNMVDRybDJIU3hhelQyZVp4aUZySDNNOXpwWGMteXlwcy1BM0VoMEY3SUNkcVplN210Z2JYakhxZXhURWo1aDIwUDJSdzBqNzdtRXlKeENMY3hmX2VSS0FuaHNRakRJTHBzWnRjQU9GMmNjT0pCMUk3SW45V3JOS0J2blVoVHRhRWp3NVRMNktTTHNIRHpfVWxNcDNoWmlVekdyblRPZw?oc=5" target="_blank">New combination treatment improves multiple myeloma outcomes</a>&nbsp;&nbsp;<font color="#6f6f6f">University of Cincinnati</font>
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPcnFGeW5VSF9uRUVjTDdUVVJIbUUxbDhPbmRlZzEyUVNyQ0tCdVo1cEYzVFJHQkVaRFRORlZkQ3NVcVNlYm13TV81bGxJSFYzbkZvWFBmbnQ4SkxmVXZ4d1pBMVNMMkFHbFNkU2h4dEdOWXFuSkxHWGR2RnY0YklmTnVpLVY4dlJsdW9RbzhtYjRTanBkenFqMVpYbnZpOHBxY3RGZQ?oc=5" target="_blank">Prelude Therapeutics Presents MPN Program Data at ASH 2025</a>&nbsp;&nbsp;<font color="#6f6f6f">The Clinical Trial Vanguard</font>
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9ZUWdlLTZ1RHl0ZURiNWtEZTlVc1BIRXN3dnhyUFdNUDFidDREcldEeW9rcE5PNUE3M2Q3VExySlFKRUV4Tms0N3hvU3ByR0VpVnMyaDNRZGhHVUlWYllLWWFreWtLdW40d3VlOGFn0gFyQVVfeXFMTVFjQ2lNZVlRV0ttYk5pMVVRNnJtQUFKSDZISnFfX0h0dUdtcjFIa3ZTZVNlWEFuMFhvTi14T2F3ME9rUWZIYkpYYUNuYWY1UXFJRGxQdmJKVW0tSndZSWJuaWFtU1lKQjFOazJjT3VTX1BR?oc=5" target="_blank">[ASH 2025] Epkinly sets new standard in relapsed/refractory follicular lymphoma</a>&nbsp;&nbsp;<font color="#6f6f6f">Korea Biomedical Review</font>
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNS0l3ZHlqc0wxNmxUaFR6Z0t5Y09xVkh6SjlQOFNWV1hFWkx3clJ3emlyOHA3Yk9sVUl5dmp3T3hPNWhqYU5xak5FS2VLaVpELUI3NWxMQXZYXzFmVllzdkRyazF4N0xpVU5CdUNsMkRmTWctZXFzcXUyWDVCR0NLM01EaXhGeVpja0tvWU5PN18tZHJlZlBuSFVR?oc=5" target="_blank">ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE1GMGdveEJQTDRLWnhVUm1VbWJlaFRDQ2wySlRhWEtFNUlrS0lOc1NQR0NXV1RTZ3lEbGNyNXFYM2RFdlhjNnViaVNvYXNnUWtka0J4SlZLYkVjQ3lLT3JtNHhoajRiSVVTUDA3Y0RyZVRDXzIxNElrTWVqVWE4QQ?oc=5" target="_blank">Ushering in a New Combination-Driven Era in MCL</a>&nbsp;&nbsp;<font color="#6f6f6f">AJMC</font>
<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxQUzVXZ1lMdElHWTIwMzVSZ1VYWkdqR2pNTkVQaFVZbFVGWWtSVEhHd3Z6Vk9VMnhXZXFLd05JcldLYVpxcGV5YWwtZFdmcVNWOUYycVp5ZDk5TlFYeWUtN1hKdExtUVczc3JoMm51dEppcWs0NG40Q25RRW9UcEtKdGl1d3pkSjVlWmt0d0lidzRXMXhRaXI2Q3RKTGVuOWZFSldab3FxNFpZNHBhRmUxVlNJWkRJbUY0WnFrSGpmdWdLdkJJSlFaMzIzOXA0RWl1cjFlV2psaVVZcWlTdTc1YzVpY0VJdGdCWVZzd0FKVm4tbkxi?oc=5" target="_blank">Epcoritamab Plus R2 in Follicular Lymphoma: A Potential New Treatment Standard</a>&nbsp;&nbsp;<font color="#6f6f6f">The ASCO Post</font>
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxQU0ZHWXFLaldCdWx2T09WWGRaREhKRGc0NmVXMUp4MDlGUUtHWGI1RmNGQm9Zb3ZqX09vRGUxV0tNcGlsLXV2SzROaEJrSFVzOEFPWDlhcjdsNmJVRzJfMjFOY3VIZDBnU2pEVF9NN25sMmRYQi1jS2VOY2E0SFdCaUlHdzE?oc=5" target="_blank">New Options in Follicular Lymphoma From ASH 2025</a>&nbsp;&nbsp;<font color="#6f6f6f">Medscape</font>
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOblIyV0pUdjBYZ0F4eU82MTNjN3l4V3NqVFVTLUVqdFFYVDc4ZkwxTmFmTDh0MjBqbVpzQVhXZWZybjBPZmQwM3pjcjIyZ0hTbFU1YmhTOE9WZ3FWUElsNnAxeldRWUNua0ZzTGllT01uN3RFQkRUVGhpVFVhaVZxZEh6QTNGRWRyeDdGRFNSNGd4SjJ1WV9kR1ZwZVVDOXM0Mk1NeWdHX2N6OGdLbHJaWA?oc=5" target="_blank">Breakthrough blood cancer research from UChicago Medicine presented at ASH 2025</a>&nbsp;&nbsp;<font color="#6f6f6f">UChicago Medicine</font>
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNc21QQ1ZrYmg5VFJTa1F5Uk5SRmNxVElqT2JJUWQ2bFZ6NjVtVVJrM0NlajJNSDRWcUc2RzF6eFZBVkotckd1N2I3Y2RXbUVkNnN4WUQyNUk3N1FCX3dielZTLWNwSVM0b2llTGgyTUgwelpjNWdiT3Z0Vkw0NklYQjB0ZUtWd2kwMldpRllLUmRpMUhUeGpST3lEbmZ0ZXU4NjZnX3dRaW5iQTVLb2swb1hMUm1JTVZBSHhMX1ZlSQ?oc=5" target="_blank">Bispecific Combo Doubles Overall Survival for Some Lymphomas, New Phase 3 Data Show</a>&nbsp;&nbsp;<font color="#6f6f6f">Oncology News Central</font>
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxOdEZKcTNSTXZiVEYzWWhJR2FvTW16bVhsdGVTR0RCZ2xwQkdsQnBLNEx1X1MyOVZNVlVJNWtNR3k4ZlRKbDdSVDU2VVcwMjRHTzROaDNWZFItay0ydVZqQTNzWVNYSWhMbWo2ZXhpenFwbkZ2d0w1VHZCTEtyUXA1cnlWOGpSZ3pEaFdmNg?oc=5" target="_blank">ASH 2025: Key Updates in CLL Therapeutics</a>&nbsp;&nbsp;<font color="#6f6f6f">Medscape</font>
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxNMDg4X29SZ2REOTE0MGNDaFpKSFljeVhpa2NVT0ZoZ3ZnRjJoZ2lqRlhiN1V3dXlONFQ0Z3V5TjNKVXhaaWctVFIyUW9QRHpPb0FkenhadGlaY0xEeEsyWTZKT3lNT3JjbEthTnZMeHlMaHdTckVIN0lxUDZZWkEzVnhULWNzMWFwaUdpaTY2bnRfVVhIRHNZYnFUdzdXSnZuTElja3h6NnhCMzNaOWxObThFSE53Q1JuQW8xZjhNZ2UyWDNrUG91eVZRYWlBOVYxMEpJ?oc=5" target="_blank">BTK Inhibitor Added to Bispecific Induces Deep Responses in High–Tumor Burden Follicular Lymphoma</a>&nbsp;&nbsp;<font color="#6f6f6f">Oncology News Central</font>
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQcUhkdmh6cWpkd2F1TWJ0NEZMRkZtbGppMU5ZcFNyY3k5SWhnTGRNOEJiWUdOdmNMcl82MGZ4VTdLbmJWNk9BVy1MTlRiLW5uUVhkczM1N3JJY3h3cjRHODMtOGJHV0NDQnZFejljaG5wUThFNXJXa3Fic0I4aEJORDNCLW5lanpXQ1FGdE1LeGRaaENYR1JhUkVCTGp4M2YxQTFUTWRFY3VQSGlhc1ZWYUVmSnFmd19QR25XSE4zZXkxUlpsOEZxUWNoSFB0ZS0ySEE?oc=5" target="_blank">Data Back Chemo-Free Approach as New Standard of Care for Ph+ ALL</a>&nbsp;&nbsp;<font color="#6f6f6f">Oncology News Central</font>
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNVjUxU3Q5TUNHdnFqT1VGLVA2MFlUYVZWQUZXLXdSdkhBU2NmODl2TEJlLXhrR2ZJNjFvamx0TUVDMkdwSEV2bk5qeXZNY2hTX1pfdVo3S3JoV3lER0t0Zk1YcmJPV0ctUXZYMzRHeEV2cWZSWGpVTDZCMThnY3F6cnZGclQtZ0p4Q21wWjViYTM?oc=5" target="_blank">A New Option Without Traditional Chemotherapy for Ph+ ALL</a>&nbsp;&nbsp;<font color="#6f6f6f">Cure Today</font>
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPdEpSRFZobGc3cEVwNGdNWHRkSmVZc0hfNFhuNWxsbXUwa0VSUUJmWHJzbVNyVGtTLXBzWUFTWXkwVXlpQ1BHcjFURmVad2xpbWJuWExTNjJmajZVT29KY0ZpT01VdFZmeWdyakRYSkQxbENMQTQtMnNsWUtZVHhtX2p0YVd3WXJ0cEd2bWszNTlla2hUbnZYZ1hKTHpnci1YTFJXQkFwV3FwWXhJXzFKQVRrV1dXZw?oc=5" target="_blank">Bispecific Combo May Offer “Functional Cure” in Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Oncology News Central</font>
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPaVpDYU16VmJWYnFGN0FnN3RCTERMeVBCZ3FlMy0xcEFYdXhWUVdMWHduZEhsM2hIckE2VmJicXh3cmdhamFUNUx2d2l1NGlEUTVDM0hiSEVncER3SmpWUmpoTUZlTHZDUmJvSG9DQTYtUThYWE1xa0pEM08zMUhkRFozQTRZR3pJUWdkcU84QldpZmdtY3NwN3YzMy1oVTZhTE1vZg?oc=5" target="_blank">Pelabresib Plus Ruxolitinib Benefits Spleen, Symptoms in Myelofibrosis</a>&nbsp;&nbsp;<font color="#6f6f6f">Targeted Oncology</font>
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE5Ya0FIV0hjVUhNOE1UVHJnQnNVSWF3VkI5UlJnaDJBajkwMk40OVRCM1lMVEZ4dVRIVHlORTJ6N2QyOEtfU3FXZURhd1NMeVVMUUtv?oc=5" target="_blank">ASH25: 83.4% of MM patients taking J&J's Tecvayli doublet alive after 3 years</a>&nbsp;&nbsp;<font color="#6f6f6f">FirstWord PHARMA</font>
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPUjhERy0yd2FHSy1ubEt5X0M1SEw2UnRlTldBZTJjYXV4NUFvNXNNQVpHWHV2VFBNblVQN3RYNXNaRndiQXYwTTQ4MXpxZlc4bDBKU3I1aHZ4UERzVE94dHNvMVUzMk5vbFVqeGVMMHU2UWRSWUloOHoyN2tzN1haTTVpRzVOMjFldVFVdVRkcGluZmliN3JqRXAyc24xTHVaTlFVc3pOUkJaazVjMVAySHloMVZhOFdIQWRqNElxaThxeTVZbG4zdEVaUHhxMFJ1Tm9fMGs2RUF6Zw?oc=5" target="_blank">ASH 2025 | Pivekimab sunirine + Ven + Aza in unfit patients with ND CD123+ AML: Phase Ib/II efficacy and safety</a>&nbsp;&nbsp;<font color="#6f6f6f">aml-hub.com</font>